- A Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Dermatomyositis — Active Not Recruiting • Phase III • NCT05437263.
- Brepocitinib, a new immune-suppressing drug, tested against placebo in adults with dermatomyositis over 52 weeks.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
This is a phase 3, multicenter, randomized, placebo-controlled, double-blind study of treatment with brepocitinib (TYK2/JAK1 inhibitor) in adults with dermatomyositis (DM). The primary objective of this study is to assess the efficacy of two dose levels of brepocitinib in comparison to placebo, as measured by differences in the Total Improvement Score (TIS). After 52 weeks of double-blind treatment, participants have the option to continue therapy in a 52 week open-label extension phase where all participants will receive brepocitinib. Conditions: Dermatomyositis Interventions: Brepocitinib, Placebo Lead Sponsor: Priovant Therapeutics, Inc. Planned Enrollment:…